Autoimmune hepetitis manegement
Reading Document
Medical Text Search
autoimmune hepatitis diagnosis criteria management treatment
Medical Text Search
autoimmune hepatitis induction remission maintenance therapy azathioprine prednisone
GradeResponse
GradeResponse
Here is a comprehensive overview of Autoimmune Hepatitis (AIH) Management:
Overview
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease driven by immune-mediated hepatocyte injury. Without treatment, it can progress to cirrhosis and liver failure. Glucocorticoid-based therapy is the cornerstone of management, with a therapeutic response achievable in up to 80% of patients (Harrison's, p. 9546).
Goals of Treatment
- Induction of remission — suppress active inflammation
- Maintenance of remission — prevent relapse with long-term therapy
- Prevention of complications — cirrhosis, liver failure
- Treatment of refractory/relapsing disease
1. Induction Therapy
Standard Regimens
| Regimen | Details |
|---|---|
| Prednisone monotherapy | Start at 40–60 mg/day (some initiate at 20 mg/day); taper over weeks–months |
| Combination therapy (preferred) | Prednisone 30 mg/day + azathioprine 50 mg/day; allows lower steroid dose, reducing side effects |
- Prednisone is favored over prednisolone by most authorities; both are equally effective (Harrison's, p. 9546).
- A popular U.S. regimen begins at 60 mg/day, tapered successively over the course of a month to a maintenance dose of 20 mg/day, then combined with azathioprine 50 mg/day.
- Combination therapy is preferred in most patients to minimize cumulative steroid exposure (especially postmenopausal women, those with diabetes, hypertension, osteoporosis, or obesity).
Biochemical Response Target
- Normalization or near-normalization of AST, ALT, bilirubin, and IgG within 6–12 months.
- Histologic remission (resolution of interface hepatitis on biopsy) may take 18–24 months to achieve.
2. Maintenance Therapy
Treatment should continue for at least 12–18 months (Harrison's, p. 9547). However, because relapse occurs in ≥50% of patients even after histologic improvement, most patients require indefinite maintenance therapy.
Maintenance Options
| Strategy | Details |
|---|---|
| Azathioprine monotherapy | 2 mg/kg/day after prednisone cessation; most effective in preserving remission |
| Low-dose prednisone | ≤10 mg/day; avoids azathioprine-associated risks (marrow suppression, teratogenicity) |
| Combination | Low-dose prednisone + azathioprine |
Azathioprine monotherapy is more effective than low-dose prednisone alone in maintaining remission (Harrison's, p. 9547). However, in young women of childbearing age, low-dose prednisone may be preferable due to azathioprine's teratogenicity.
3. Monitoring During Treatment
- LFTs (AST, ALT, ALP, bilirubin, albumin), INR — every 1–3 months during induction; every 3–6 months during maintenance
- IgG levels — useful marker of disease activity
- CBC — monitor for azathioprine-induced cytopenias
- TPMT/NUDT15 genotyping — before starting azathioprine to identify poor metabolizers at risk of severe myelosuppression
- Liver biopsy — considered before stopping therapy to confirm histologic remission
4. Stopping Therapy
A trial of withdrawal can be considered after:
- Minimum 2–3 years of treatment
- At least 18–24 months of sustained biochemical remission
- Confirmed histologic remission on liver biopsy (no interface hepatitis)
Even then, relapse rate is ≥50%. Patients must be monitored closely after withdrawal.
5. Refractory / Relapsing Disease
| Situation | Management |
|---|---|
| Incomplete response | Optimize doses; consider re-biopsy to confirm diagnosis |
| Relapse after withdrawal | Reinstate therapy at induction doses; plan for longer maintenance |
| Steroid-refractory AIH | Second-line agents (see below) |
| Azathioprine intolerance | Switch to mycophenolate mofetil (MMF) 1–1.5 g twice daily |
Second-Line Agents
- Mycophenolate mofetil (MMF) — most widely used alternative to azathioprine; effective in azathioprine-intolerant patients
- Tacrolimus or cyclosporine — calcineurin inhibitors used in truly refractory cases
- Budesonide — an alternative to prednisone with less systemic side effects, but NOT suitable in patients with cirrhosis (due to loss of first-pass hepatic metabolism)
6. Special Situations
| Population | Considerations |
|---|---|
| Cirrhosis at presentation | Treat aggressively; response can still occur; transplant evaluation if decompensated |
| Acute severe AIH (fulminant) | IV methylprednisolone; early liver transplant evaluation if no response in 7 days |
| Pregnancy | Prednisolone preferred (over prednisone); azathioprine generally avoided in first trimester |
| Children | Similar regimens; closer monitoring for growth and bone health |
| Elderly | Higher risk of steroid side effects; prefer combination therapy with lower steroid dose |
7. Liver Transplantation
Indicated for:
- Acute liver failure unresponsive to medical therapy
- End-stage cirrhosis (decompensated — ascites, variceal bleeding, hepatic encephalopathy)
- Hepatocellular carcinoma (HCC) within Milan criteria
Post-transplant recurrence of AIH occurs in 10–35% of patients and requires immunosuppression continuation.
Summary Algorithm
AIH Diagnosed
|
▼
Induction: Prednisone 40–60 mg/day ± Azathioprine 50 mg/day
|
▼ (over 6–18 months)
Biochemical/Histologic Remission?
YES → Taper to maintenance (Azathioprine 2 mg/kg/day ± low-dose prednisone)
NO → Optimize dose → Consider 2nd-line (MMF, Tacrolimus)
|
▼
Maintain ≥2–3 years → Trial of withdrawal with close monitoring
|
▼
Relapse → Reinstate therapy → Likely indefinite maintenance
References: Harrison's Principles of Internal Medicine, 21st Edition, pp. 9546–9547.
This is a shared conversation. Sign in to Orris to start your own chat.